메뉴 건너뛰기




Volumn 5, Issue 2, 2011, Pages 426-432

The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: Results from the PIOfIx study

Author keywords

Inflammation; Oral antidiabetics; Pioglitazone plus metformin; Platelet aggregation; Type 2 diabetes; Vascular function

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; THROMBOXANE; VON WILLEBRAND FACTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; LIGAND; SULFONYLUREA DERIVATIVE;

EID: 84855879504     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500233     Document Type: Article
Times cited : (28)

References (37)
  • 2
    • 35348876837 scopus 로고    scopus 로고
    • Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function
    • Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther. 2007;9(5):410-20.
    • (2007) Diabetes Technol Ther , vol.9 , Issue.5 , pp. 410-420
    • Borchert, M.1    Schöndorf, T.2    Lübben, G.3    Forst, T.4    Pfützner, A.5
  • 4
    • 3042779108 scopus 로고    scopus 로고
    • Platelet activation, inflammatory mediators and hypercholesterolemia
    • Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol. 2003;1(2):157-69.
    • (2003) Curr Vasc Pharmacol , vol.1 , Issue.2 , pp. 157-169
    • Ferroni, P.1    Basili, S.2    Davi, G.3
  • 5
    • 33745017446 scopus 로고    scopus 로고
    • Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty
    • Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res. 2006;3(1):52-6.
    • (2006) Diab Vasc Dis Res , vol.3 , Issue.1 , pp. 52-56
    • Yngen, M.1    Norhammar, A.2    Hjemdahl, P.3    Wallén, N.H.4
  • 6
    • 0043167980 scopus 로고    scopus 로고
    • Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects
    • Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003;27(8):907-11.
    • (2003) Int J Obes Relat Metab Disord , vol.27 , Issue.8 , pp. 907-911
    • Tamminen, M.1    Lassila, R.2    Westerbacka, J.3    Vehkavaara, S.4    Yki-Järvinen, H.5
  • 8
    • 85039641741 scopus 로고    scopus 로고
    • The fixed combination of pioglitazone with metformin improves biomarkers of chronic systemic inflammation and platelet function in comparison to metformin + glimepiride. Results from the PIOfix study
    • Pfützner AH, Forst T, Löbig M, Schöndorf T, Hohberg C, Braun M, Lehmann U, Fuchs W, Pfützner A. The fixed combination of pioglitazone with metformin improves biomarkers of chronic systemic inflammation and platelet function in comparison to metformin + glimepiride. Results from the PIOfix study. Diabetes. 2010;59(Suppl 1):A200-1.
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Pfützner, A.H.1    Forst, T.2    Löbig, M.3    Schöndorf, T.4    Hohberg, C.5    Braun, M.6    Lehmann, U.7    Fuchs, W.8    Pfützner, A.9
  • 9
    • 33645277645 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
    • Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 2006;8(1):28-36.
    • (2006) Diabetes Technol Ther , vol.8 , Issue.1 , pp. 28-36
    • Pfützner, A.1    Forst, T.2
  • 10
    • 14744287439 scopus 로고    scopus 로고
    • Pathobiology and cell interactions of platelets in diabetes
    • Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res. 2005;2(1):16-23.
    • (2005) Diab Vasc Dis Res , vol.2 , Issue.1 , pp. 16-23
    • Stratmann, B.1    Tschoepe, D.2
  • 11
    • 33751524662 scopus 로고    scopus 로고
    • Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects
    • Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17(8):577-85.
    • (2006) Platelets , vol.17 , Issue.8 , pp. 577-585
    • Vaidyula, V.R.1    Boden, G.2    Rao, A.K.3
  • 12
    • 33645678090 scopus 로고    scopus 로고
    • Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus
    • Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005;57 Suppl:42-58.
    • (2005) Pharmacol Rep , vol.57 , Issue.SUPPL. , pp. 42-58
    • Watala, C.1    Boncler, M.2    Gresner, P.3
  • 13
    • 0033485806 scopus 로고    scopus 로고
    • Hemodynamic shear stress and its role in atherosclerosis
    • Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035-42.
    • (1999) JAMA , vol.282 , Issue.21 , pp. 2035-2042
    • Malek, A.M.1    Alper, S.L.2    Izumo, S.3
  • 14
    • 20444495375 scopus 로고    scopus 로고
    • Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study
    • Pfützner A, Marx N, LübbenvG, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-31.
    • (2005) J Am Coll Cardiol , vol.45 , Issue.12 , pp. 1925-1931
    • Pfützner, A.1    Marx, N.2    Lübbenv, G.3    Langenfeld, M.4    Walcher, D.5    Konrad, T.6    Forst, T.7
  • 15
    • 56249121001 scopus 로고    scopus 로고
    • Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease
    • Von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res. 2008;5(4):310-8.
    • (2008) Diab Vasc Dis Res , vol.5 , Issue.4 , pp. 310-318
    • Von Bibra, H.1    Diamant, M.2    Scheffer, P.G.3    Siegmund, T.4    Schumm-Draeger, P.M.5
  • 16
    • 0033821518 scopus 로고    scopus 로고
    • The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects
    • Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 2000;43(9):1099-106.
    • (2000) Diabetologia , vol.43 , Issue.9 , pp. 1099-1106
    • Yudkin, J.S.1    Panahloo, A.2    Stehouwer, C.3    Emeis, J.J.4    Bulmer, K.5    Mohamed-Ali, V.6    Denver, A.E.7
  • 17
    • 3843140669 scopus 로고    scopus 로고
    • C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones
    • Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004;21(8):810-7.
    • (2004) Diabet Med , vol.21 , Issue.8 , pp. 810-817
    • Nesto, R.1
  • 18
    • 33846273797 scopus 로고    scopus 로고
    • Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study
    • Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49(3):290-7.
    • (2007) J Am Coll Cardiol , vol.49 , Issue.3 , pp. 290-297
    • Hanefeld, M.1    Marx, N.2    Pfützner, A.3    Baurecht, W.4    Lübben, G.5    Karagiannis, E.6    Stier, U.7    Forst, T.8
  • 19
    • 43549097824 scopus 로고    scopus 로고
    • The IRIS V study: Pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions
    • Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther. 2008;10(3):206-12.
    • (2008) Diabetes Technol Ther , vol.10 , Issue.3 , pp. 206-212
    • Karagiannis, E.1    Pfützner, A.2    Forst, T.3    Lübben, G.4    Roth, W.5    Grabellus, M.6    Flannery, M.7    Schöndorf, T.8
  • 21
    • 67649841976 scopus 로고    scopus 로고
    • Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone - Results from a post-marketing surveillance trial under daily routine conditions
    • Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone - results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol Ther 2009;11(6):379-83.
    • (2009) Diabetes Technol Ther , vol.11 , Issue.6 , pp. 379-383
    • Schöndorf, T.1    Karagiannis, E.2    Posseldt, R.E.3    Forst, T.4    Pfützner, A.5
  • 22
    • 84973349634 scopus 로고    scopus 로고
    • PIOace-Study: Pioglitazone, but not ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk
    • Pfützner A, Hanefeld M, Afzal-Dekordi L, Müller J, Kleine I, Fuchs W, Forst T. PIOace-Study: pioglitazone, but not ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk. Diabetologia. 2009;52 (Suppl 1):S335-6.
    • (2009) Diabetologia , vol.52 , Issue.SUPPL. 1
    • Pfützner, A.1    Hanefeld, M.2    Afzal-Dekordi, L.3    Müller, J.4    Kleine, I.5    Fuchs, W.6    Forst, T.7
  • 24
    • 2642522886 scopus 로고    scopus 로고
    • Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: Relationships to cardiovascular disease and risk factor intervention
    • Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109(21):2524-8.
    • (2004) Circulation , vol.109 , Issue.21 , pp. 2524-2528
    • Lim, H.S.1    Blann, A.D.2    Lip, G.Y.3
  • 25
    • 4143126478 scopus 로고    scopus 로고
    • CD40 ligand: A novel target in the fight against cardiovsacular disease
    • Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovsacular disease. Ann Pharmacother. 2004;38(9):1500-8.
    • (2004) Ann Pharmacother , vol.38 , Issue.9 , pp. 1500-1508
    • Vishnevetsky, D.1    Kiyanista, V.A.2    Gandhi, P.J.3
  • 28
    • 14744284119 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects
    • Chu JW, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Tsao PS. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res. 2005;2(1):37-41.
    • (2005) Diab Vasc Dis Res , vol.2 , Issue.1 , pp. 37-41
    • Chu, J.W.1    Abbasi, F.2    Lamendola, C.3    McLaughlin, T.4    Reaven, G.M.5    Tsao, P.S.6
  • 29
    • 0242543997 scopus 로고    scopus 로고
    • The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
    • Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;42(10):1757-63.
    • (2003) J Am Coll Cardiol , vol.42 , Issue.10 , pp. 1757-1763
    • Sidhu, J.S.1    Cowan, D.2    Kaski, J.C.3
  • 31
    • 32844469572 scopus 로고    scopus 로고
    • Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    • Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2006;97(5):646-50.
    • (2006) Am J Cardiol , vol.97 , Issue.5 , pp. 646-650
    • Chu, C.S.1    Lee, K.T.2    Lee, M.Y.3    Su, H.M.4    Voon, W.C.5    Sheu, S.H.6    Lai, W.T.7
  • 33
    • 40949098983 scopus 로고    scopus 로고
    • Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation
    • Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008;197(2):718-24.
    • (2008) Atherosclerosis , vol.197 , Issue.2 , pp. 718-724
    • Khanolkar, M.P.1    Morris, R.H.2    Thomas, A.W.3    Bolusani, H.4    Roberts, A.W.5    Geen, J.6    Jackson, S.K.7    Evans, L.M.8
  • 34
    • 72649105693 scopus 로고    scopus 로고
    • The effect of rosiglitazone on the expression of thrombogenic markers in leukocytes in type 2 diabetes mellitus
    • Svobodová H, Stulc T, Kasalová Z, Dolezalová R, Marinov I, Capek P, Ceska R. The effect of rosiglitazone on the expression of thrombogenic markers in leukocytes in type 2 diabetes mellitus. Physiol Res. 2009;58(5):701-7.
    • (2009) Physiol Res , vol.58 , Issue.5 , pp. 701-707
    • Svobodová, H.1    Stulc, T.2    Kasalová, Z.3    Dolezalová, R.4    Marinov, I.5    Capek, P.6    Ceska, R.7
  • 35
    • 53349153475 scopus 로고    scopus 로고
    • Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials
    • Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221-38.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.12 , pp. 1221-1238
    • Mannucci, E.1    Monami, M.2    Lamanna, C.3    Gensini, G.F.4    Marchionni, N.5
  • 36
    • 78649772977 scopus 로고    scopus 로고
    • Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes mellitus
    • Greenwich
    • Perez A, Jacks R, Arora V, Spanheimer R. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2010;12(12):973-82.
    • (2010) J Clin Hypertens , vol.12 , Issue.12 , pp. 973-982
    • Perez, A.1    Jacks, R.2    Arora, V.3    Spanheimer, R.4
  • 37
    • 40849134281 scopus 로고    scopus 로고
    • Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive10)
    • PROactive Study Investigators
    • Wilcox R, Kupfer S, Erdmann E, PROactive Study Investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive10). Am Heart J. 2008;155(4):712-7.
    • (2008) Am Heart J , vol.155 , Issue.4 , pp. 712-717
    • Wilcox, R.1    Kupfer, S.2    Erdmann, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.